• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22345 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2014     NIHR Horizon Scanning Centre (NIHR HSC) Tabalumab for systemic lupus erythematosus
2023     National Institute for Health and Care Excellence (NICE) Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal). NICE technology appraisal guidance 923
2000     VA Technology Assessment Program (VATAP) Tablet splitting
2016     NIHR Health Technology Assessment programme Tackling obesity in areas of high social deprivation: clinical effectiveness and cost-effectiveness of a task-based weight management group programme a randomised controlled trial and economic evaluation
2001     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Tacrolimus
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tacrolimus (Advagraf®)
2009     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tacrolimus (Advagraf®) for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tacrolimus (Envarsus®)
1997     Wessex Institute for Health Research and Development (WIHRD) Tacrolimus after kidney transplantation
2004     Quality Improvement Scotland (NHS QIS ) Tacrolimus and pimecrolimus for atopic eczema
2004     National Institute for Health and Care Excellence (NICE) Tacrolimus and pimecrolimus for atopic eczema
2006     Canadian Agency for Drugs and Technologies in Health (CADTH) Tacrolimus for Crohn's disease
2001     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Tacrolimus ointment for the treatment of atopic dermatitis
2008     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tacrolimus prolonged-release (Advagraf®)
2002     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) TACTICS: Transfusion Associated Complications or Transfusion Induced Complications - primary research
2006     Institute for Clinical Effectiveness and Health Policy (IECS) Tactile devices in audiology
2006     Institute for Clinical Effectiveness and Health Policy (IECS) Tactile devices in audiology
2015     NIHR Horizon Scanning Centre (NIHR HSC) Tadalafil (Cialis) for Duchenne muscular dystrophy
2013     National Institute for Health and Care Excellence (NICE) Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal). NICE technology appraisal guidance 273
2010     NIHR Horizon Scanning Centre (NIHR HSC) Tafamidis for transthyretin amyloid polyneuropathy
2024     Agency for Care Effectiveness (ACE) Tafamidis for treating transthyretin amyloid cardiomyopathy
2021     National Institute for Health and Care Excellence (NICE) Tafamidis for treating transthyretin amyloidosis with cardiomyopathy. NICE technology appraisal guidance 696
2023     National Institute for Health and Care Excellence (NICE) Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma. NICE technology appraisal guidance 883
2022     National Institute for Health and Care Excellence (NICE) Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal). NICE technology appraisal guidance 782
2013     HAYES, Inc. Tai chi for improving balance and function in patients with parkinson's disease
2015     NIHR Horizon Scanning Centre (NIHR HSC) Talazoparib for locally advanced and/or metastatic breast cancer with germline BRCA 1/2 positive mutation
2024     National Institute for Health and Care Excellence (NICE) Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations. NICE technology appraisal guidance 952
2016     HAYES, Inc. Talimogene laherparepvec (T-VEC; Imlygic) for treatment of unresectable melanoma lesions
2007     Adelaide Health Technology Assessment (AHTA) Tam Pap for self testing of HPV
1999     Alberta Heritage Foundation for Medical Research (AHFMR) Tamaflu (R) (oseltamivir phosphate)
1999     ECRI Tamoxifen for reduction of breast cancer incidence in healthy women at high risk
2011     HAYES, Inc. Tandem autologous peripheral blood stem cell transplantation for neuroblastoma
2015     HAYES, Inc. Tandem autologous stem cell transplant for Hodgkin lymphoma
2007     HAYES, Inc. Tandem mass spectrometry for metabolic disease screening of newborns
2002     HAYES, Inc. Tandem mass spectrometry for metabolic screening of newborns
2007     NIHR Horizon Scanning Centre (NIHR HSC) Tap water home haemodialysis systems for end stage renal failure: horizon scanning technology briefing
2009     NIHR Horizon Scanning Centre (NIHR HSC) Tapentadol (Palexia) for severe acute pain
2009     NIHR Horizon Scanning Centre (NIHR HSC) Tapentadol (Palexia) prolonged-release for severe chronic pain
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tapentadol prolonged release (Palexia® SR)
2008     NIHR Horizon Scanning Centre (NIHR HSC) Taranabant (MK-0364) for obesity
2007     NIHR Horizon Scanning Centre (NIHR HSC) Tarenflurbil (Flurizan, R-Flurbiprofen) for Alzheimer’s disease – mild
2020     Institute for Clinical and Economic Review (ICER) Targeted immune modulators for ulcerative colitis: effectiveness and value
2007     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Targeted radionuclide therapy with 90Y- and 177-Lu-DOTATOC in patients with neuroendocrine tumors
2008     Adelaide Health Technology Assessment (AHTA) Targeted screening for abdominal aortic aneurysm
2010     Adelaide Health Technology Assessment (AHTA) Targeted screening for cardiovascular risk for all adults between 40-74 years
2020     Malaysian Health Technology Assessment (MaHTAS) Targeted therapies in combination with hormonal therapy as a first-line treatment for HR+ and HER2- metastatic breast cancer
2021     Malaysian Health Technology Assessment (MaHTAS) Targeted therapies in combination with neoadjuvant chemotherapy for HER2-positive breast cancer and economic evaluation
2023     National Institute for Health and Care Excellence (NICE) Targeted-release budesonide for treating primary IgA nephropathy. NICE technology appraisal guidance 937
2014     NIHR Health Services and Delivery Research programme Targeting the Use of Reminders and Notifications for Uptake by Populations (TURNUP): a systematic review and evidence synthesis
2022     NIHR Health Technology Assessment programme Targeting vascular adhesion protein-1 (VAP-1) for the treatment of liver fibrosis: a study of efficacy and mechanisms in patients with primary sclerosing cholangitis (PSC)
2022     NIHR Health Technology Assessment programme TARGIT-B: An international randomised controlled trial to compare targeted intra-operative radiotherapy boost with conventional external beam radiotherapy boost after lumpectomy for breast cancer in women with a high risk of local recurrence
2006     NIHR Horizon Scanning Centre (NIHR HSC) Taribavirin hydrochloride for chronic hepatitis C virus: horizon scanning review
2010     NIHR Horizon Scanning Centre (NIHR HSC) Taspoglutide for type 2 diabetes mellitus - add-on therapy
2014     NIHR Horizon Scanning Centre (NIHR HSC) Tasquinimod for chemotherapy naïve, metastatic hormone-relapsed prostate cancer
2001     NIHR Health Technology Assessment programme Taxanes (breast cancer): update
2001     NIHR Health Technology Assessment programme Taxanes (ovarian cancer): update
2007     NIHR Health Technology Assessment programme Taxanes for the adjuvant treatment early breast cancer: systematic review and economic evaluation
2007     NIHR Health Technology Assessment programme Taxanes for the adjuvant treatment early breast cancer: systematic review and economic evaluation
2000     HAYES, Inc. Taxol treatment for breast cancer
2000     HAYES, Inc. Taxol treatment for non-small-cell lung cancer
2000     HAYES, Inc. Taxol treatment for ovarian cancer
2011     HAYES, Inc. Tay-Sachs Disease (TSD) testing in individuals of non–ashkenazi jewish origin
2011     HAYES, Inc. Taylor spatial frame (Smith&Nephew Inc.) for posttraumatic lower limb deformity
1999     Alberta Heritage Foundation for Medical Research (AHFMR) Tc-99m labelled antibody fragment for osteomyelitis
2014     Health Quality Ontario (HQO) Team-based models for end-of-life care: an evidence-based analysis
2012     HAYES, Inc. Tearlab osmolarity system (TearLab Corp.) for diagnosis of dry eye disease
2011     HAYES, Inc. TearLab osmolarity system (TearLab Corp.) for diagnosis of dry eye disease
2001     HAYES, Inc. Technetium-99m depreotide scintigraphy for detection of pulmonary malignancy
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Techniques and products for surgical hand antisepsis: a review of guidelines
2006     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) Techniques and technologies in medical hydrology and hydrotherapy. IPE-06/50
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Techniques for renal biopsy: guidelines
2015     NIHR Health Technology Assessment programme Techniques for the interruption of tubal patency for female sterilisation
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Techniques for the management of temporary epicardial pacemaker leads: clinical evidence, safety, and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Techniques to improve the use of diagnostic laboratory test ordering: clinical evidence
2023     NIHR Health Technology Assessment programme Techniques to increase lumbar puncture success in newborn babies: the NeoCLEAR RCT
2000     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Technological innovation and strategic plan 2001-2004 - expert panel
1999     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Technological watch
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Technologies assisting in remote consultations for the diagnosis of stroke: a review of the clinical evidence
2005     Medical Advisory Secretariat (MAS) Technologies for osteoarthritis of the knee: an evidence-based analysis
2020     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Technologies for the diagnosis of prostate cancer
2009     Agenzia nazionale per i servizi sanitari regionali (Agenas) Technologies for the identification of osteoporosis
2011     Adelaide Health Technology Assessment (AHTA) Technologies for the inactivation/reduction of pathogens in blood products
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Technologies to reduce errors in dispensing and administration of medication in hospitals: clinical and economic analyses
1999     Alberta Heritage Foundation for Medical Research (AHFMR) Technologies used for managing and preventing acute myocardial infarction (HEAT 1). (First in series on the Health Expenditure and Technology project, jointly with the Institute of Health Economics)
1993     Institute of Technology Assessment (ITA) Technology and Ageing I: safety alarm systems and counseling for housing adaption
1996     Institute of Technology Assessment (ITA) Technology and Ageing II: European initiatives, neighbourhood-initiatives, Internet-services
1991     Institute of Technology Assessment (ITA) Technology and Ageing: The maintenance of independency and self-determination of aged people
1996     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) Technology assessment and coverage policy: the case of invasive cardiology therapy in 5 European countries
1998     Finnish Office for Health Care Technology Assessment (Finohta) Technology assessment in nursing: a systematic review of the national and international literature
2014     Agency for Healthcare Research and Quality (AHRQ) Technology assessment of molecular pathology testing for the estimation of prognosis for common cancers
2013     Agency for Healthcare Research and Quality (AHRQ) Technology assessment on genetic testing or molecular pathology testing of cancers with unknown primary site to determine origin
2023     Scottish Health Technologies Group (SHTG) Technology enabled theatre scheduling tools
2023     Scottish Health Technologies Group (SHTG) Technology-enabled theatre scheduling systems
2023     National Institute for Health and Care Excellence (NICE) Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal). NICE technology appraisal guidance 869
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) TECNIS® or Acrysof® soft intraocular lenses for patients undergoing cataract surgery: benefits and harms, clinical effectiveness, cost-effectiveness, and guidelines
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tedizolid phosphate (Sivextro®)
2017     HAYES, Inc. Teduglutide (Gattex; Shire-NPS Pharmaceuticals Inc.) to reduce parenteral support requirements in adults with short bowel syndrome
2016     NIHR Horizon Scanning Centre (NIHR HSC) Teduglutide (Revestive) - short bowel syndrome: in paediatric patients aged 1-17 years who are dependent on parenteral nutrition
2009     NIHR Horizon Scanning Centre (NIHR HSC) Teduglutide for short bowel syndrome
2022     National Institute for Health and Care Excellence (NICE) Teduglutide for treating short bowel syndrome. NICE technology appraisal guidance 804